A traditional Chinese medicine composition and its uses
The combination of triterpenoids and astragaloside A, a traditional Chinese medicine, solves the problem of cardiotoxicity caused by chemotherapy drugs, protects myocardial cells, and improves the safety and effectiveness of chemotherapy.
Patent Information
- Application Number
- CN202311783302.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-22
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-12-22
AI Technical Summary
Existing chemotherapy drugs such as doxorubicin cause serious cardiotoxicity problems in anti-tumor treatment, especially DOX cardiotoxicity, which limits its clinical use.
The combination of traditional Chinese medicine ingredients, including triterpenoids and astragaloside A, works by invigorating qi and promoting blood circulation, removing blood stasis and promoting new tissue growth, and synergistically protecting the heart and reducing the damage of chemotherapy drugs to the myocardium.
It significantly protects cardiomyocytes, reduces the toxic effects of chemotherapy drugs on the heart, improves the safety and effectiveness of chemotherapy treatment regimens, and prolongs patient life.
Smart Images

Figure CN117752671B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedicine, specifically to a traditional Chinese medicine composition and its use, and more specifically to a traditional Chinese medicine composition containing triterpenoids and astragaloside A and its use in cardioprotective drugs, belonging to the field of modern application technology of traditional Chinese medicine. Background Technology
[0002] Malignant tumors (commonly known as cancer) are a leading cause of death in my country and globally, characterized by their high incidence and mortality rate. Various treatment options have been developed worldwide for malignant tumors, including surgery, chemotherapy, radiotherapy, and biological therapy. Among these, chemotherapy, with its versatility and ease of implementation, is one of the most commonly used cancer treatments.
[0003] Chemotherapy utilizes small-molecule cytotoxic agents to inhibit tumor cell growth or kill cancer cells. While it offers advantages such as convenient administration and ease of implementation, chemotherapy drugs inevitably produce some toxicity to the proliferation of normal cells in the body. Anthracyclines are recognized as highly effective antitumor drugs, widely used for malignant solid tumors and malignant tumors of the lymphatic and hematologic systems. Although anthracyclines, represented by doxorubicin (DOX), have significant anticancer efficacy, their cardiotoxicity is the most common and serious cardiovascular toxicity related to anticancer treatment, a major cause of complications and death in cancer survivors, severely limiting their clinical use. The mechanism of DOX cardiotoxicity is complex, involving oxidative stress, mitochondrial damage, iron overload, apoptosis, and autophagy, among which oxidative stress is the core factor in DOX cardiotoxicity.
[0004] Trillaginyin is a typical natural saponin compound, widely found in plants such as Trillium, Dioscorea opposita, and Dioscorea cirrhosa. Chinese Patent CN105232891A discloses the application of Trillium extract and its saponins in the preparation of drugs for treating ischemic heart disease. Chinese Patent CN107375310A discloses the use of trillaginyin in the preparation of drugs for treating heart failure. Chinese Patent CN1511535A discloses the use of trillaginyin in the preparation of drugs for treating cardiovascular and cerebrovascular diseases.
[0005] Astragaloside A is a drug extracted from Astragalus membranaceus and is one of the main active ingredients of Astragalus membranaceus. It has the effects of strengthening cardiac contractility, protecting the myocardium, and resisting heart failure. For example, astragaloside A can reduce myocardial damage in diabetic myocardial infarction rats. Deng Changqing, Zhang Jinglan, Jin Haitao. Exploring the mechanism of action of astragaloside A in reducing myocardial damage in diabetic myocardial infarction rats based on the NRF2 / FPN1 pathway [J]. Western Medicine, 2023, 35(10):1439-1443+1451. Summary of the Invention
[0006] The purpose of this invention is to overcome the problem of significant cardiotoxicity associated with chemotherapy drugs in anti-tumor treatment, and to provide a traditional Chinese medicine composition and its uses. Specifically, it is a pharmaceutical composition and its use in drugs that protect against chemotherapy-induced myocardial cell damage. The traditional Chinese medicine composition of this invention has excellent effects in alleviating or reducing the cardiotoxic effects of chemotherapy drugs.
[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0008] A traditional Chinese medicine composition comprising triterpenoid glycoside and astragaloside A.
[0009] There are no existing reports on the combined use of triterpenoids and astragaloside A. According to traditional Chinese medicine theory, cardiac damage caused by antitumor drugs is attributed to qi deficiency and blood stasis due to external pathogenic factors. The combination of triterpenoids and astragaloside A invigorates qi and blood, removes blood stasis and promotes tissue regeneration, breaks up stagnation and dissipates nodules, thus restoring balance after the pathogenic factors are eliminated. Therefore, it can effectively alleviate / treat symptoms of myocardial damage caused by chemotherapy. Cell experiments have confirmed that the drug composition of triterpenoids and astragaloside A has a good protective effect against cardiac damage caused by chemotherapy drugs, especially doxorubicin-induced cardiac damage. Therefore, the combination of triterpenoids and astragaloside A in this invention, which synergistically protects the heart, has very high pharmaceutical development and application value.
[0010] Furthermore, the traditional Chinese medicine composition of the present invention can be summarized as a closed-type composition: a traditional Chinese medicine composition consisting of triterpenoid and astragaloside A. This is a drug composed solely of triterpenoid and astragaloside A, used for protecting the heart.
[0011] Furthermore, in the traditional Chinese medicine composition, the weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 1-5 parts astragaloside A.
[0012] Experimental studies have determined that a weight ratio of 1:1 to 5 of triterpenoid and astragaloside A can better exert their synergistic effect in protecting the heart, reducing or mitigating or eliminating the cardiotoxic side effects of chemotherapy drugs, especially the cardiotoxic effects of doxorubicin.
[0013] Furthermore, the weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 4 parts astragaloside A.
[0014] Furthermore, the weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 5 parts astragaloside A.
[0015] A pharmaceutical composition comprising the aforementioned traditional Chinese medicine composition and a pharmaceutically acceptable adjuvant. The term "pharmaceutically acceptable" refers to material that is not biologically or otherwise undesirable (i.e., does not cause undesirable biological effects at an unacceptable level or interacts in a harmful manner).
[0016] Pharmaceutically acceptable adjuvants include any one or more of the following: solvents, propellants, solubilizers, cosolvents, disintegrants, lubricants, fillers, flavoring agents, antibacterial agents, antioxidants, coating agents, penetration enhancers, pH adjusters, surfactants, thickeners, and protectants. Adjuvant raw materials may be used in single-ingredient or two-or-more-ingredient-ingredient combinations.
[0017] Furthermore, the pharmaceutical composition is formulated into any of the following preparations: tablets, capsules, injections, granules, suppositories, pills, ointments, creams, pastes, sprays, gels, syrups, tinctures, patches, etc.
[0018] Furthermore, the triterpenoid glycoside and / or astragaloside A may be replaced entirely or partially with their derivatives.
[0019] The term "derivative" refers to a compound having a structure derived from a parent compound and whose structure has a high degree of similarity to the compounds disclosed in this invention, and which a person skilled in the art can predict will exhibit the same or similar activity / utility as the compounds disclosed in this invention. Alternatively, like a prodrug, it can be metabolized by an organism to produce a compound with the same or similar activity and utility as the compounds of this invention. Exemplary derivatives include inorganic salts, organic salts, esters, amides, salts of esters or amides, and N-oxides of the parent compound.
[0020] Pharmaceutical uses of the traditional Chinese medicine combination of triterpenoid and astragaloside A.
[0021] Furthermore, the use of the traditional Chinese medicine composition of triterpenoid and astragaloside A in the preparation of a cardioprotective drug.
[0022] Preferably, the use of the traditional Chinese medicine composition of triterpenoid and astragaloside A in the preparation of a myocardial cell protective drug.
[0023] Preferably, the drug is a drug for protecting against doxorubicin-induced cardiac damage. The traditional Chinese medicine composition of triterpenoid and astragaloside A of the present invention has a good protective effect against doxorubicin-induced cardiac damage.
[0024] Trillagin and astragaloside A have not been reported in the treatment of myocardial injury caused by chemotherapy drugs. This invention's research reveals that the combination of trillagin and astragaloside A exhibits superior cardioprotective effects, a finding that is unprecedented. The composition can protect the heart, thus possessing the potential for use in the preparation of cardioprotective pharmaceuticals.
[0025] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0026] 1. This invention proposes a traditional Chinese medicine composition of triterpenoid and astragaloside A, which has a good protective effect against cardiac damage caused by chemotherapy drugs. Cell experiments have confirmed that it has a significant protective effect against DOX-induced myocardial cell damage.
[0027] 2. This invention proposes a traditional Chinese medicine composition of triterpenoids and astragaloside A, which can effectively alleviate or reduce the cardiotoxicity of chemotherapy drugs (such as doxorubicin). This provides more adjuvant treatment options for malignant tumors, can improve chemotherapy regimens, and is expected to enhance the efficacy of chemotherapy in malignant tumor patients and prolong their lives. Attached Figure Description
[0028] Figure 1 This is the effect of each monomer component in Experiment Example 1 on the survival rate of H9c2 cardiomyocytes.
[0029] Figure 2 This is the effect of different concentrations of each monomer component in Experiment Example 1 on the survival rate of DOX-induced H9c2 cardiomyocytes.
[0030] Figure 3 This study examines the effects of the optimal concentrations of each monomer component and the drug composition in Experiment Example 1 on the survival rate of H9c2 cardiomyocytes, myocardial enzymes LDH and cTnT.
[0031] Figure 4 This study examines the effects of the optimal concentrations of each monomer component and the drug composition on the levels of SOD and GSH in H9c2 cardiomyocytes in Experiment Example 2.
[0032] Figure 5 This is the effect of each monomer component and drug composition of Experiment Example 3 on the survival rate of H9c2 cardiomyocytes, myocardial enzymes LDH and cTnT.
[0033] Figure 6 This refers to the effects of the monomeric components and drug composition of Experiment 4 on echocardiographic parameters LVEF, LVFS, and LIVDs in C57 mice.
[0034] Figure 7 This is the effect of each monomer component and drug composition of Experiment 5 on serum myocardial enzymes CK-MB and LDH in C57 mice. Detailed Implementation
[0035] To more clearly describe the inventive objectives, technical solutions, and advantages of the specific embodiments of the present invention, the solutions in the specific embodiments will be described in detail below with reference to the accompanying drawings. The specific technical solutions involved in the following specific embodiments are merely for the purpose of clearly and completely describing the innovative technical solutions of the present invention. They are only a part of the specific implementation methods that the present invention can adopt, not all of the embodiments, and should not be construed as limiting the innovative solutions of the present invention.
[0036] The triterpenoid and astragaloside A used in the following experiments are known compounds and were obtained commercially.
[0037] Example 1
[0038] Trillium glycoside, astragaloside A, and a monomeric combination of trillium glycoside and astragaloside A on doxorubicin-induced H9c2 cardiomyocytes Effects on survival rate and myocardial enzymes
[0039] H9c2 cardiomyocytes were resuspended in DMEM complete medium, and then the cell suspension was transferred to culture flasks and cultured at 37°C in a 5% CO2 incubator. After the cells reached the logarithmic growth phase, H9c2 cardiomyocytes were cultured at a rate of 1×10⁻⁶ cells / mL. 5 After seeding H9c2 cardiomyocytes per well in 96-well plates for 24 hours, the experimental wells were treated with different concentrations of triterpenoid and astragaloside A solutions for 24 hours. Blank wells were treated with complete culture medium, and negative control wells were treated with DMSO. The survival rate of cardiomyocytes at different concentrations of each monomer component was detected by MTT assay to investigate the toxicity of each group to cardiomyocytes.
[0040] Cell viability = [(experimental wells - negative control wells) / (blank wells - negative control wells)] × 100%
[0041] Note: In the figure, ** indicates that P < 0.01 compared to the control group.
[0042] The results are as follows Figure 1 As shown in Figure AB, triterpenoid and astragaloside A have no toxic effects on cardiomyocytes at concentrations of 0-16 μM and 0-160 μM, respectively.
[0043] A doxorubicin (DOX)-induced injury model of H9c2 cardiomyocytes was used. H9c2 cardiomyocytes were resuspended in DMEM complete medium, and then the cell suspension was transferred to culture flasks and cultured at 37°C in a 5% CO2 incubator. After the cells reached the logarithmic growth phase, H9c2 cardiomyocytes were cultured at a rate of 1×10⁻⁶ cells / year. 5 After seeding cells per well in 96-well plates for 24 hours, the experimental groups were treated with different concentrations of triterpenoid and astragaloside A solutions, respectively, in combination with DOX (4 μM) for 24 hours. The control group received neither the test substance nor DOX, and the DOX group received no test substance. Cell viability was assessed using the MTT assay to determine the optimal concentration of each monomeric compound.
[0044] Note: Table 1, Figure 1 In the table, ## represents P < 0.01 compared to the control group; ** represents P < 0.01 compared to the model group. The results are shown in Table 1. Figure 1 As shown in Figure AB, the optimal concentrations of triterpenoid and astragaloside A are 2 μM and 40 μM, respectively.
[0045] Table 1. Survival rate (%) of H9c2 cells after treatment with different concentrations of triterpenoid and astragaloside A
[0046]
[0047] H9c2 cardiomyocytes were co-treated with DOX (4 μM) for 24 h using the optimal concentrations of the components and drug compositions. Cell viability was detected by the MTT assay. The effects of each compound and drug composition on the survival rate of cardiomyocyte injury model and myocardial enzymes LDH and cTnT were compared.
[0048] Table 2. H9c2 cell viability and myocardial enzyme levels after treatment with triterpenoid glycoside, astragaloside A, and other compounds.
[0049]
[0050] Note: Table 2, Figure 2 In the figures, ## represents P < 0.01 compared to the DOX group; ** represents P < 0.01 compared to the DOX group; and && represents P < 0.01 compared to the drug composition group.
[0051] The results are shown in Table 2. Figure 2 As shown in Figure AB, both triterpenoid and astragaloside A at their optimal concentrations have significant protective effects against doxorubicin-induced H9c2 cardiomyocyte damage.
[0052] The results are as follows Figure 3 As shown in Figures AB, triterpenoid 8 μM, astragaloside A 40 μM, and triterpenoid 4 μM + astragaloside A 20 μM all improved cell viability, myocardial enzymes LDH and cTnT, with the triterpenoid 4 μM + astragaloside A 20 μM group showing the best effect.
[0053] Example 2
[0054] In a model of doxorubicin-induced H9c2 cardiomyocyte injury, the effects of triterpenoid glycoside, astragaloside A, and a drug combination on SOD and GSH levels. The influence of level
[0055] H9c2 cardiomyocytes were resuspended in DMEM complete medium, and then the cell suspension was transferred to culture flasks and cultured at 37°C in a 5% CO2 incubator. H9c2 cardiomyocytes were then cultured at a rate of 5 × 10⁻⁶ cells / mL. 5Cardiomyocytes were seeded per well in 12-well plates for 24 h, with the following groups: blank control, DOX (4 μM), triterpenoid 8 μM, astragaloside 40 μM, and triterpenoid 4 μM + astragaloside 20 μM. Each group was treated with the corresponding concentration of drug and doxorubicin (4 μM) for 24 h. The blank control group received complete culture medium, while the DOX group received an equal volume of doxorubicin (4 μM) solution. After incubation, the intermediate-efficiency RIPA cell lysis buffer was mixed with protease inhibitors and phosphatase inhibitors at a ratio of 100:1 to obtain cell lysis buffers. Cell proteins were quantified using a BCA kit, and the levels of SOD and GSH in cardiomyocytes were measured with and without DOX treatment according to the kit instructions.
[0056] Table 3. SOD and GSH levels in H9c2 cells treated with triterpenoid glycoside, astragaloside A, and other combinations.
[0057]
[0058] Note: In the table, ## represents P < 0.01 compared with the DOX group; * represents P < 0.05 compared with the DOX group; ** represents P < 0.01 compared with the DOX group; and & represents P < 0.05 compared with the drug composition group.
[0059] The results are as follows Figure 4 As shown in Figure AB, compared with the blank group, the levels of SOD and GSH in cardiomyocytes in the DOX group were significantly reduced (P < 0.01); compared with DOX, the levels of SOD and GSH in cardiomyocytes in the 8 μM triterbinazone, 40 μM astragaloside A, and 4 μM triterbinazone + 20 μM astragaloside A groups were increased (P < 0.01 or P < 0.05), among which the 4 μM triterbinazone + 20 μM astragaloside A group showed the best effects in many indicators.
[0060] Example 3
[0061] Effects of tribulus glycoside, astragaloside A, and a combination of tribulus glycoside and astragaloside A monomers on doxorubicin-induced H9c2 cardiomyocyte survival and myocardial enzymes
[0062] H9c2 cardiomyocytes were resuspended in DMEM complete medium, and then the cell suspension was transferred to culture flasks and cultured at 37°C in a 5% CO2 incubator. After the cells reached the logarithmic growth phase, H9c2 cardiomyocytes were cultured at a rate of 1×10⁻⁶ cells / mL. 5After seeding cells per well in 96-well plates for 24 hours, the experimental groups were treated with DOX (4 μM) for 24 hours with tribulus glycoside solution (8 μM), astragaloside A solution (8 μM), tribulus glycoside (4 μM), and a mixture of astragaloside A and DOX (4 μM). The control group received neither the test substance nor DOX, and the DOX group received no test substance. Cell viability was assessed using the MTT assay to determine the optimal concentration of each monomeric compound.
[0063] Table 4. H9c2 cell viability and myocardial enzyme levels after treatment with triterpenoid glycoside, astragaloside A, and the combination.
[0064]
[0065] Note: Table 4 Figure 5 In the figures, ## represents P < 0.01 compared to the DOX group; * represents P < 0.05 compared to the DOX group; ** represents P < 0.01 compared to the DOX group; & represents P < 0.05 compared to the drug composition group; and && represents P < 0.01 compared to the drug composition group.
[0066] The results are shown in Table 4. Figure 5 As shown in the AC, triterpenoid solution (8 μM), astragaloside A solution (8 μM), triterpenoid (4 μM) and astragaloside A (4 μM) mixed solution all had significant protective effects against doxorubicin-induced H9c2 cardiomyocyte damage, and all could reduce myocardial enzymes LDH and cTnT. Among them, the triterpenoid 4 μM + astragaloside A 4 μM group had the best effect.
[0067] Example 4
[0068] Echocardiography of a doxorubicin-induced C57 mouse cardiotoxicity model using triterpenoids, astragaloside A, and a drug combination. Impact of indicators
[0069] Fifty male C57BL / 6 mice were acclimatized for one week and then randomly divided according to body weight into a blank control group, a DOX group, a tribulus glycoside 50 mg / kg group, an astragaloside IV group, and a tribulus glycoside 25 mg / kg + astragaloside IV group. Except for the blank group, all mice in each group received intraperitoneal injections of doxorubicin 5 mg / kg once a week for 5 weeks, with a dosage of 0.2 mL / 10 g. Each group was administered the corresponding drug concentration daily, while the blank group received the corresponding volume of distilled water by gavage at a dosage of 0.1 mL / 10 g for 6 weeks. One hour after the last administration, mice were anesthetized with isoflurane, and echocardiographic parameters LVEF, LVFS, and LVIDs were measured.
[0070] Table 5. Echocardiographic parameters of C57 mice after treatment with triterpenoid glycoside, astragaloside A, and the combination.
[0071]
[0072] Note: Table 5 Figure 6 In the figures, ## represents P < 0.01 compared to the DOX group; * represents P < 0.05 compared to the DOX group; ** represents P < 0.01 compared to the DOX group; & represents P < 0.05 compared to the drug composition group; and && represents P < 0.01 compared to the drug composition group.
[0073] The results are shown in Table 5. Figure 6 As shown in the AC results, compared with the blank group, the DOX group mice showed significantly decreased LVEF and LVFS levels and significantly increased LVIDs (P < 0.01); compared with DOX, the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group mice showed significantly increased LVEF and LVFS levels (P < 0.01), while the astragaloside A 200 mg / kg group and the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group mice showed significantly decreased LVIDs (P < 0.05 or P < 0.01), with the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group showing the best effect.
[0074] Example 5
[0075] Effects of triterpenoid glycoside, astragaloside A, and drug combination on myocardial enzymes in an doxorubicin-induced C57 mouse cardiotoxicity model
[0076] Fifty male C57BL / 6 mice were acclimatized for one week and then randomly divided according to body weight into four groups: a blank control group, a DOX group, a tribulus glycoside 50 mg / kg group, an astragaloside IV group, and a tribulus glycoside 25 mg / kg + astragaloside IV group. Except for the blank control group, all mice in each group received intraperitoneal injections of doxorubicin 5 mg / kg once a week for 5 weeks, with a dosage of 0.2 mL / 10 g. Each group was administered the corresponding drug concentration daily, while the blank control group received the corresponding volume of distilled water by gavage at a dosage of 0.1 mL / 10 g for 6 weeks. One hour after the last administration, blood was collected under isoflurane anesthesia, centrifuged, and serum CK-MB and LDH levels were measured using a kit.
[0077] Table 6. Cardiac enzymes in C57 mice after treatment with triterpenoid glycoside, astragaloside A, and the combination.
[0078]
[0079]
[0080] Note: Figure 7 In the figures, ## represents P < 0.01 compared to the DOX group; * represents P < 0.05 compared to the DOX group; ** represents P < 0.01 compared to the DOX group; and & represents P < 0.05 compared to the drug composition group.
[0081] The results are shown in Table 6. Figure 7 As shown in Figures AB, compared with the blank group, the CK-MB and LDH levels of mice in the DOX group were significantly increased (P < 0.01); compared with DOX, the CK-MB level of mice in the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group was significantly decreased (P < 0.05), and the LDH levels of mice in the astragaloside A 200 mg / kg group and the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group were significantly decreased (P < 0.05 or P < 0.01), among which the tribulus glycoside 25 mg / kg + astragaloside A 100 mg / kg group had the best effect.
[0082] For those skilled in the art, when understanding the solutions described in the specific embodiments of the present invention, conventional technical manuals in the field can be consulted, such as the 2020 edition of the Pharmacopoeia of the People's Republic of China. At the same time, for the places where technical terms appear, appropriate understanding or adjustment can be made for reference, and the same or similar technical solutions can be derived without creative effort.
[0083] The above embodiments describe only the basic principles, main features and / or advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and the description of the invention content in the specification are only the principles or specific cases of the present invention. Without departing from the essence of the innovative idea of the present invention, there are various changes and improvements to the innovative solution of the present invention, and all such changes and improvements fall within the scope of protection claimed by the present invention.
Claims
1. A traditional Chinese medicine composition for protecting against doxorubicin-induced cardiac damage, characterized in that, The traditional Chinese medicine composition consists of triterpenoid glycoside and astragaloside A, with the following weight ratio: 1 part triterpenoid glycoside and 4-5 parts astragaloside A.
2. The traditional Chinese medicine composition for protecting against doxorubicin-induced cardiac damage according to claim 1, characterized in that, The weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 4 parts astragaloside A.
3. The traditional Chinese medicine composition for protecting against doxorubicin-induced cardiac damage according to claim 1, characterized in that, The weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 5 parts astragaloside A.
4. A pharmaceutical composition for protecting against doxorubicin-induced cardiac damage, characterized in that, The pharmaceutical composition comprises the traditional Chinese medicine composition of claim 1, and pharmaceutically acceptable adjuvants; pharmaceutically acceptable adjuvants include any one or more of the following: solvents, propellants, solubilizers, cosolvents, disintegrants, lubricants, fillers, flavoring agents, antibacterial agents, antioxidants, coating agents, penetration enhancers, pH adjusters, surfactants, thickeners, and protectants.
5. The pharmaceutical composition for protecting against doxorubicin-induced cardiac damage according to claim 4, characterized in that, The pharmaceutical composition is formulated into any of the following preparations: tablets, capsules, injections, granules, suppositories, pills, ointments, creams, pastes, sprays, gels, syrups, tinctures, and patches.
6. The use of a traditional Chinese medicine composition of triterpenoid and astragaloside A in the preparation of a drug for protecting against doxorubicin-induced cardiac damage, characterized in that, The weight ratio of triterpenoid glycoside and astragaloside A is: 1 part triterpenoid glycoside and 4-5 parts astragaloside A.
Citation Information
Patent Citations
Preparation method of wake robin extracts and saponins of wake robin extracts and application of wake robin extracts and saponins to preparation of medicine for resisting ischemic heart disease
CN105232891A
Application of diosgenin glucoside in preparation of medicine for treating cardiac failure
CN107375310A
Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease
CN1511535A
Application of dioscin monomer in preparation of medicine for treating myocardial cell injury caused by chemotherapy
CN116785307A
